The economic implications of treating atherothrombotic disease in australia, from the government perspective

Clinical Therapeutics

Volumn 32, Issue 1, 2010, Pages 119-132

  Ademi, Zanfina ^a   Liew, Danny ^b   Hollingsworth, Bruce ^a   Wolfe, Rory ^a   Steg, Gabriel P ^c   Bhatt, Deepak L ^d   Reid, Christopher M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c INSERM   (France)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

aged; atherothrombosis; direct health care costs

Indexed keywords

AGED; ARTICLE; ATHEROSCLEROSIS; AUSTRALIA; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; COST; ECONOMICS; FOLLOW UP; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INSURANCE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; STATISTICS; THROMBOSIS;

AGED; ATHEROSCLEROSIS; AUSTRALIA; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; COSTS AND COST ANALYSIS; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PERIPHERAL VASCULAR DISEASES; THROMBOSIS;

EID: 77952304861     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.009     Document Type: Article

References (35)

1. Bakhai, A, The burden of coronary, cerebrovascular and peripheral arterial disease. PharmacoEconomics. 22:Suppl 4 (2004), 11–18.
2. Watkins, LO, Epidemiology and burden of cardiovascular disease. Clin Cardiol. 27:Suppl 3 (2004), III2–III6.
3. Leys, D, Atherothrombosis: A major health burden. Cerebrovasc Dis. 11:Suppl 2 (2001), 1–4.
4. Begg, S, Vos, T, Barker, B, et al. The Burden of Disease and Injury in Australia 2003, 2007, Australian Institute of Health and Welfare, Canberra, Australia.
5. National Heart Foundation of Australia. The Shifting Burden of Cardiovascular Disease in Australia. Access Economics Pty Limited, 2005 http://www.heartfoundation.org.au/SiteCollectionDocuments/cvd%20shifting%20burden.pdf Accessed February 2, 2009.
6. Chapko, MK, Liu, CF, Perkins, M, et al. Equivalence of two healthcare costing methods: Bottom-up and top-down. Health Econ. 18 (2009), 1188–1201.
7. Reid, C, Nelson, MR, Shiel, L, et al. Australians at risk: Management of cardiovascular risk factors in the REACH Registry. Heart Lung Circ. 17 (2008), 114–118.
8. Ohman, EM, Bhatt, DL, Steg, PG, et al., for the REACH Registry Investigators. The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 151 (2006), 786.e1–786.e10.
9. Medicare Australia statistics. Pharmaceutical benefits schedule item reports, September 2006 to September 2007 https://www.medicareaustralia.gov.au/statistics/pbs_item.shtml Accessed February 2, 2009.
10. Department of Health and Ageing. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners. Effective 1 September 2007-30 September 2007. http://www.pbs.gov.au/html/healthpro/publication/view?date=20070901&type=FlashPaper&name=generalschedule Accessed February 2, 2009.
11. Ademi, Z, Liew, D, Chew, D, et al., REACH Registry Investigators. Drug treatment and cost of cardiovascular disease in Australia. Cardiovasc Ther. 27 (2009), 164–172.
12. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Reducing risk in heart disease 2007. Guidelines for preventing cardiovascular events in people with coronary heart disease. http://www.heartfoundation.org.au/SiteCollectionDocuments/A%20RR%20RRIHD%202008Update%20Guideline%20pdf.pdf Updated 2008. Accessed February 2, 2009.
13. Smith, SC Jr, Allen, J, Blair, SN, et al., for the AHA/ACC, National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention with coronary and other atherosclerotic vascular disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute [published correction appears in Circulation. 2006;113: e847]. Circulation. 113 (2006), 2363–2372.
14. Department of Health and Ageing. Medicare Benefits Schedule book, November 2007 http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/D25CFA71D62D2439CA2574F9002B42CD/$File/2007-11-MBS.pdf Accessed April 11, 2009.
15. Medicare Australia. http://www.medicareaustralia.gov.au/ Accessed April 11, 2009.
16. Department of Health and Ageing. Round 11 (2006-07) Cost report-public version 5.1, private version 4.2 and 5.1. http://www.healthemergency.gov.au/internet/main/publishing.nsf/Content/Round_11-cost-reports Accessed February 2, 2009.
17. Southern Medical Association. Casemix views. http://www.sma.org.sg/sma_news/3202/report.pdf Accessed December 19, 2009.
18. Duckett, SJ, The Australian Health Care System, 3rd ed., 2007, Oxford University Press, South Melbourne, Australia.
19. Duckett, SJ, Casemix funding for acute hospital inpatient services in Australia. Med J Aust. 169:Suppl (1998), S17–S21.
20. Barber, JA, Thompson, SG, Analysis of cost data in randomized trials: An application of the non-parametric bootstrap. Stat Med. 19 (2000), 3219–3236.
21. Migliaccio-Walle, K, Caro, JJ, Ishak, KJ, O'Brien, JA, Costs and medical care consequences associated with the diag-nosis of peripheral arterial disease. Pharmaco Economics. 23 (2004), 733–742.
22. Levy, E, Gabriel, S, Dinet, J, The comparative medical costs of atherothrombotic disease in European countries. Pharmaco Economics. 21 (2003), 651–659.
23. Mahoney, EM, Wang, K, Cohen, DJ, et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 1 (2008), 38–45.
24. Vlayen, J, De Backer, G, Peers, J, et al. Atherosclerotic cardiovascular diseases in Belgium: A cost-of-illness analysis. Cardiovasc Drugs Ther. 22 (2008), 487–494.
25. Steg, PG, Bhatt, DL, Wilson, PW, et al., REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 297 (2007), 1197–1206.
26. Bhatt, DL, Steg, PG, Ohman, EM, et al., REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 295 (2006), 180–189.
27. Hooi, JD, Stoffers, HE, Kester, AD, et al. Peripheral arterial occlusive disease: Prognostic value of signs, symptoms, and the ankle-brachial pressure index. Med Decis Making. 22 (2002), 99–107.
28. Hirsch, AT, Criqui, MH, Treat-Jacobson, D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 286 (2001), 1317–1324.
29. Sicras-Mainar, A, Navarro-Artieda, R, Rejas-Gutiérrez, J, et al. Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain. BMC Fam Pract., 8, 2007, 60.
30. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348 (1996), 1329–1339.
31. Revised PBS criteria for lipidmodifying drugs, October 2006 http://www.nps.org.au/_data/assets/pdf_file/0020/23717/pbs_lmd_criteria.pdf Accessed April 4, 2009.
32. Amarenco, P, Labreuche, J, Lipid management in the prevention of stroke: Review and updated metaanalysis of statins for stroke prevention. Lancet Neurol. 8 (2009), 453–463.
33. Senes, S, Penm, E, Medicines for Cardiovascular Health: Are They Used Appropriately? Cardiovascular Disease Series no. 27, 2007, Australian Institute of Health and Welfare, Canberra, Australia.
34. Top 10 drugs. Australian Prescriber, 31, 2008, 164 http://www.australianprescriber.com/upload/pdf/articles/993.pdf Accessed March 10, 2009.
35. Ademi Z, Liew D, Chew D, et al. Predictors of annual pharmaceutical costs in Australia for participants with or at high risk of cardiovascular disease. Am J Cardiovasc Drugs. In press.